英国再生医学产品报销的新情况：出版物、政策与政治
The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
作者信息
Mahalatchimy Aurélie, Faulkner Alex
机构信息
Centre for Global Health Policy, School of Global Studies, University of Sussex, Falmer Brighton, BN1 9RH, UK.
CNRS, Aix Marseille Université, Université de Toulon, Université Pau & Pays Adour, DICE, CERIC, International Comparative & European Law, Aix en Provence, France.
出版信息
Regen Med. 2017 Sep;12(6):611-622. doi: 10.2217/rme-2017-0041. Epub 2017 Oct 3.
AIM
This paper aims to map the trends and analyze key institutional dynamics that constitute the policies for reimbursement of regenerative medicine (RM), especially in the UK.
MATERIALS & METHODS: Two quantitative publications studies using Google Scholar and a qualitative study based on a larger study of 43 semi-structured interviews.
RESULTS
Reimbursement has been a growing topic of publications specific to RM and independent from orphan drugs. Risk-sharing schemes receive attention among others for dealing with RM reimbursement. Trade organizations have been especially involved on RM reimbursement issues and have proposed solutions.
CONCLUSION
The policy and institutional landscape of reimbursement studies in RM is a highly variegated and conflictual one and in its infancy.
目的
本文旨在梳理相关趋势，并分析构成再生医学报销政策的关键制度动态，尤其是在英国。
材料与方法
两项使用谷歌学术的定量出版物研究，以及一项基于对43次半结构化访谈的更大规模研究的定性研究。
结果
报销一直是再生医学特有的、独立于孤儿药的出版物中日益热门的话题。风险分担计划在处理再生医学报销问题方面受到了特别关注。贸易组织尤其参与了再生医学报销问题，并提出了解决方案。
结论
再生医学报销研究的政策和制度格局高度多样化且充满冲突，尚处于起步阶段。
Zotero 插件